India, Feb. 2 -- While reporting financial results for the fourth quarter on Friday, biopharmaceutical company Bristol-Myers Squibb Co. (BMY) initiated its adjusted earnings and revenue growth guidance for the full-year 2024.
For fiscal 2024, the company now projects adjusted earnings in a range of $7.10 to $7.40 per share on a worldwide total revenue growth in the low single-digits.
On average, 23 analysts polled by Thomson Reuters expect the company to report earnings of $7.00 per share on revenues growth of 1.9 percent to $45.58 billion for the year. Analysts' estimates typically exclude special items.
For the fourth quarter, the company reported net income attributable to Bristol-Myers Squibb of $1.76 billion or $0.87 per share, lowe...